Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Phase 2
10
about 7.8 years
18+
3 sites in NY, RI, WI
What this study is about
This trial is testing a new treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel for pancreatic adenocarcinoma. The goal is to see if this combination can shrink tumors, prolong life, and be safe for patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cemiplimab
- 2.Take Gemcitabine
- 3.Take Motixafortide
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cemiplimab, gemcitabine, motixafortide, paclitaxel (Taxane chemotherapy; stabilizes microtubules)
injection (Injection), injection, subcutaneous, infusion
Primary: Overall Response Rate (Complete Response (CR) + Partial Response (PR))
Secondary: Disease Control Rate, Median Overall Survival, Median Progression Free Survival
Oncology